AI Article Synopsis
- Alemtuzumab (ALZ) is a monoclonal antibody used to treat recurrent remittent multiple sclerosis (RRMS) by depleting CD52-expressing T and B cells, while preserving stem and innate immune cells.
- Long-term studies have linked ALZ to autoimmune diseases like thrombocytopenic purpura and thyroiditis, with two new reported cases of autoimmune hemophilia A (AHA) following ALZ infusion in Brazil.
- AHA is a serious condition that can be life-threatening if not treated quickly, highlighting the need for specific coagulation tests and monitoring after ALZ treatment.
Article Abstract
Alemtuzumab (ALZ) is an anti-CD52 monoclonal antibody used to treat recurrent remittent multiple sclerosis (RRMS). After ALZ infusion, there is a depletion of T and B cells expressing CD52, while the stem cells and innate immune cells are spared. Longitudinal studies with long periods of follow-ups have reported ALZ-associated autoimmune diseases, such as thrombocytopenic purpura and thyroiditis. We report two patients who developed autoimmune hemophilia A or acquired hemophilia (AHA) after ALZ infusion, one of whom developed severe vitiligo. To the best of our knowledge, these two cases of ALZ-associated AHA are the first two cases to be reported in Brazil, and the fourth and fifth AHA cases to be reported worldwide. AHA is a potential life-threatening disease if not diagnosed and treated in a timely manner. The development of AHA should be cited as a possible adverse event, and specific coagulation tests must be part of the official recommendations for patient follow-ups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2020.102181 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!